# Estradiol Risk Stratification Protocol
## Functional Medicine Reference Ranges (2024-2025)

---

# MEN - Estradiol (pg/mL)

## Reference Ranges
| Category | Range (pg/mL) | Clinical Context |
|----------|---------------|-----------------|
| **Conventional** | 10-40 | Standard lab reference |
| **Functional Optimal** | 20-40 | Optimal health window |
| **Deficient** | <10 | Bone loss, vasomotor symptoms |
| **At-Risk (Low)** | 10-20 | Suboptimal, monitor symptoms |
| **Excessive** | >50-60 | Cardiovascular, metabolic risk |

## Age-Specific Medians (Lean, Healthy Men)
- Ages 20-39: 32.0-37.0 pg/mL
- Ages 40-59: 29.6-33.9 pg/mL
- Ages 60+: 27.0-34.5 pg/mL
- *Decline: ~1-2% per year after age 40*

## Functional Medicine Optimal Range: **20-40 pg/mL**
- Peak health window for bone density, mood, libido, cardiovascular function
- Minimum for vasomotor symptom prevention: **≥25 pg/mL**
- Minimum to prevent bone loss: **≥19 pg/mL**

---

## LOW ESTRADIOL IN MEN (<10 pg/mL)
### Clinical Significance & Symptoms

**Bone & Skeletal:**
- Increased osteoporosis risk & fracture susceptibility
- Joint pain & stiffness
- Reduced bone mineralization

**Sexual & Reproductive:**
- Reduced libido & sexual dysfunction
- Decreased morning erections
- Erectile dysfunction

**Metabolic & Body Composition:**
- Muscle loss & weakness
- Increased abdominal fat accumulation
- Insulin resistance
- Weight gain tendency

**Cardiovascular:**
- Impaired endothelial function
- Increased cardiovascular disease risk

**Neurological & Mood:**
- Fatigue & low energy
- Mood swings & irritability
- Cognitive impairment (memory, focus, concentration)
- Brain function decline

---

## HIGH ESTRADIOL IN MEN (>50-60 pg/mL)
### Clinical Significance & Aromatization Risk

**Mechanism:**
- Aromatase enzyme (primarily fat tissue) converts testosterone → estradiol
- Excess body fat creates positive feedback loop (↑E2 → ↑fat storage)
- Exogenous testosterone therapy increases risk

**Contributing Factors:**
- Obesity (abdominal fat especially)
- Alcohol consumption (↑aromatase activity)
- Liver dysfunction (impaired estrogen clearance)
- Testosterone replacement therapy (dose-dependent)

**Clinical Manifestations:**
- Gynecomastia (breast tissue enlargement)
- Sexual dysfunction (reduced libido, erectile dysfunction)
- Mood disturbances & emotional lability
- Unexplained weight gain despite exercise
- Cardiovascular event risk (U-shaped curve)

**Long-Term Health Risks:**
- Increased cardiac involvement & mortality (2019 meta-analysis)
- Metabolic dysfunction & diabetes risk
- Accelerated fat deposition
- Potential prostate changes (under investigation)

**Management:**
- Weight loss via diet/exercise (primary intervention)
- Monitor if on TRT
- Consider aromatase modulation (consult practitioner)
- Target sweet spot: 20-40 pg/mL (not "as low as possible")

---

# WOMEN - Estradiol by Menstrual Cycle Phase

## Early Follicular Phase (Days 1-7, Menses)
| Metric | Conventional | Functional Optimal | Units |
|--------|-------------|--------------------|-------|
| **Range** | 25-75 | 30-60 | pg/mL |
| **Baseline E2** | 21-251 | 30-60 | pg/mL |
| **LC-MS/MS** | 31-771 | 100-300 | pmol/L |

**Characteristics:**
- Lowest E2 of cycle
- Triggers FSH rise & follicle recruitment
- Endometrium thin
- Low progesterone

---

## Mid-Follicular Phase (Days 7-11)
| Metric | Conventional | Functional Optimal | Units |
|--------|-------------|--------------------|-------|
| **Range** | 40-120 | 60-150 | pg/mL |
| **Progression** | Gradual rise | Steady increase | — |

**Characteristics:**
- Follicle growth acceleration
- E2 doubles from early follicular
- Estrogen feedback begins
- Pre-surge preparation

---

## Ovulatory Phase (Peri-Ovulation, ~Day 14)
| Metric | Conventional | Functional Optimal | Units |
|--------|-------------|--------------------|-------|
| **Mid-Cycle Peak** | 100-400 | 200-400 | pg/mL |
| **Pre-LH Surge** | 200-600 | 250-400 | pg/mL |
| **LC-MS/MS Peak** | 275-2,864 | 900-1,600 | pmol/L |

**Characteristics:**
- Sharp 24-48hr surge before ovulation
- Triggers LH surge → egg release
- Critical for fertility
- Peak fertility window

---

## Luteal Phase (Post-Ovulation, Days 15-28)
| Metric | Conventional | Functional Optimal | Units |
|--------|-------------|--------------------|-------|
| **Early Luteal** | 50-150 | 80-200 | pg/mL |
| **Mid Luteal** | 75-300 | 100-250 | pg/mL |
| **Late Luteal** | 30-200 | 50-150 | pg/mL |
| **LC-MS/MS** | 95-1,941 | 350-710 | pmol/L |

**Mid-Luteal (Days 19-21) - OPTIMAL TEST TIMING:**
- Progesterone at peak
- Use for Pg/E2 ratio assessment
- Most accurate hormone balance picture
- 5-7 days post-ovulation (ideal test window)

---

# POST-MENOPAUSAL WOMEN

## Estradiol Levels
| Status | Range (pg/mL) | Clinical Notes |
|--------|---------------|-----------------|
| **No HRT** | 5-25 | Varies widely; mean ~20 |
| **Symptomatic threshold** | <5 | Hot flashes, night sweats peak |
| **Symptom improvement** | ≥15 | Symptoms subside at this level |
| **Bone protection threshold** | ≥60 | Prevents bone loss |

## Hormone Replacement Therapy (HRT)
| Therapy Goal | Target Range | Clinical Benefit |
|--------------|--------------|-----------------|
| **Symptom relief (50% women)** | 60 pg/mL (220 pmol/L) | Hot flashes, night sweats |
| **Bone loss prevention** | 60 pg/mL (220 pmol/L) | Maintains bone mineral density |
| **Optimal symptomatic control** | 60-150 pg/mL (220-550 pmol/L) | Standard HRT goal range |
| **Real-world median (transdermal)** | 96 pg/mL (355 pmol/L) | Observational data 2024 |
| **Real-world range (transdermal)** | 20-560 pg/mL (73-2,050 pmol/L) | Wide interindividual variation |

**Critical Finding:** ~25% of women on highest licensed dose remain subtherapeutic (<60 pg/mL) and may benefit from off-label dosing.

## When to Consider HRT
- Moderate-severe vasomotor symptoms unresponsive to lifestyle
- Bone loss (osteopenia/osteoporosis)
- Vaginal atrophy/genitourinary syndrome
- Cognitive decline related to estrogen withdrawal
- Cardiovascular risk reduction (within 10 yrs of menopause)

---

# FUNCTIONAL MEDICINE FRAMEWORKS

## OptimalDX Ranges
| Population | Range (pg/mL) | Notes |
|------------|---------------|-------|
| **Men** | 20-40 (optimal) | <10 = bone loss risk; >50 = cardiovascular risk |
| **Menstruating women** | 30-800 (cycle-dependent) | Varies by phase dramatically |
| **Postmenopausal (no HRT)** | <7-20 | Often asymptomatic below 20 |
| **Postmenopausal (on HRT)** | 60-150 | Treatment target range |

## DUTCH Test (Precision Analytical)
**Dried urine hormone metabolites - NOT serum estradiol**

| Population | Range (ng/mg) | Context |
|------------|---------------|---------|
| **Premenopausal follicular** | 0.2-0.7 | Early cycle |
| **Premenopausal luteal** | 4.0-12.0 | Mid-luteal optimal window |
| **Postmenopausal** | 1.0-2.0 | Natural menopause range |

**Advantage:** LC/MS assay shows clear gap between postmenopausal & luteal (eliminates overlap diagnostic confusion)

## ZRT Laboratory (Saliva Testing)
| Population | Range (pg/mL) | Assessment Notes |
|------------|---------------|------------------|
| **Women (classical)** | 0.0-5.0 | ±2SD approach |
| **Women (refined)** | 1.3-3.3 | 20th-80th percentile |
| **Hot flash threshold** | <1.0 | Peak symptom severity |
| **Symptom improvement** | ≥1.3 | Substantial relief at this level |
| **Men** | 0.4-0.8 (free) | Saliva = bioavailable fraction |

**Note:** Saliva measures free/bioavailable fraction (not total). LC-MS extraction essential for accuracy at low concentrations.

---

# ESTROGEN DOMINANCE (Functional Medicine Concept)

## Definition
Relative excess of estrogen compared to progesterone, not necessarily absolute E2 elevation.

## Mechanisms
- **Liver dysfunction:** Impaired estrogen detoxification/clearance
- **Gut dysfunction:** Poor reabsorption of deconjugated estrogens
- **Progesterone deficiency:** Inadequate corpus luteum production (anovulation, luteal phase defect)
- **Body fat excess:** Aromatase activity in adipose tissue
- **Xenoestrogen exposure:** Plastics, pesticides, cosmetics
- **Chronic stress:** Progesterone → cortisol shunting

## Associated Health Risks
- Breast cancer (relative risk increase)
- Thyroid dysfunction
- Uterine fibroids & endometriosis
- Autoimmune disease acceleration
- Mood & anxiety disorders
- Weight gain (especially upper body/breasts)

## Assessment Tools
- Pg/E2 ratio (luteal phase)
- DUTCH metabolites (estrogen metabolite ratios)
- Symptom correlation
- Complete hormone panel

---

# PROGESTERONE-ESTRADIOL RATIO (Pg/E2)

## Optimal Range
**100-500 pg/mL** (Pg/E2 ratio)
- **Optimal target:** ~300 within range
- **Test timing:** Mid-luteal phase (days 19-21)
- **Optimal progesterone:** 8-30 ng/mL (luteal)
- **Optimal estradiol:** 60-100 pg/mL (luteal)

## Interpretation
| Ratio | Status | Clinical Significance |
|-------|--------|----------------------|
| **<100** | Estrogen dominance | Relative progesterone deficiency |
| **100-500** | Balanced | Optimal hormonal ratio |
| **>500** | Progesterone dominance | Often from supplementation/overcorrection |

**Critical:** Ratio only meaningful when E2 is in normal luteal range. Cannot assess if E2 is in follicular range.

## Why the Ratio Matters
- Absolute levels less important than balance
- Unopposed estrogen = increased proliferation risk
- Progesterone provides protective, antiproliferative effect
- Cyclical variation normal; consistent imbalance pathologic

---

# UNIT CONVERSIONS & TECHNICAL NOTES

## pg/mL to pmol/L
- **Conversion factor:** 1 pg/mL = 3.671 pmol/L
- **US standard:** pg/mL (picograms/milliliter)
- **European standard:** pmol/L (picomoles/liter)

## Assay Methods (Clinical Significance)
| Method | Accuracy | Best For | Limitations |
|--------|----------|----------|------------|
| **LC-MS/MS** | High (gold standard) | All populations, low-level detection | Expensive, specialized labs |
| **Immunoassay** | Variable | Men, postmenopausal | Poor at low concentrations; cross-reactivity |
| **Saliva (ZRT extraction)** | High (bioavailable fraction) | Functional assessment | Not total E2; specialized interpretation |
| **DUTCH (urine metabolites)** | High (metabolite patterns) | Liver clearance assessment | Not serum E2; metabolite-specific |

**Clinical Pearl:** Request LC-MS/MS for men and postmenopausal women (lower concentrations require precision).

---

# RISK STRATIFICATION SUMMARY

## MEN - Risk Tiers
| E2 Level | Risk Category | Action |
|----------|---------------|--------|
| **<10 pg/mL** | HIGH RISK (Deficiency) | Evaluate cause; monitor bone, cognition, sexual function |
| **10-20 pg/mL** | MODERATE RISK | Consider monitoring; address modifiable causes |
| **20-40 pg/mL** | OPTIMAL | Maintain; annual monitoring |
| **40-50 pg/mL** | BORDERLINE ELEVATED | Assess symptoms; evaluate aromatization sources |
| **>50 pg/mL** | HIGH RISK (Excess) | Evaluate (TRT, obesity, liver); intervention indicated |

## WOMEN (Follicular Phase) - Risk Tiers
| E2 Level | Risk Category | Action |
|----------|---------------|--------|
| **<20 pg/mL** | DEFICIENT | May indicate ovarian insufficiency or anovulation |
| **20-40 pg/mL** | SUBOPTIMAL | Weak follicle development; assess FSH, cycle regularity |
| **40-80 pg/mL** | OPTIMAL | Healthy follicle growth |
| **>100 pg/mL (early follicular)** | ELEVATED | Rule out PCOS, preexisting corpus luteum |

## WOMEN (Luteal Phase, Mid-Cycle Testing) - Risk Tiers
| E2 Level | Risk Category | Pg/E2 Ratio | Action |
|----------|---------------|------------|--------|
| **<40 pg/mL (luteal)** | DEFICIENCY | Likely >500 | Weak ovulation; assess ovarian reserve |
| **40-80 pg/mL** | SUBOPTIMAL | 200-400 | Borderline; assess progesterone; monitor cycle |
| **80-150 pg/mL** | OPTIMAL | 100-400 | Healthy ovulation; balanced hormones |
| **>150 pg/mL** | ELEVATED | <100 | PCOS, estrogen dominance concern; confirm Pg level |

## WOMEN (Postmenopausal, Not on HRT)
| E2 Level | Risk Category | Action |
|----------|---------------|--------|
| **<5 pg/mL** | VERY LOW | Peak hot flash risk; assess HRT candidacy |
| **5-20 pg/mL** | LOW (expected) | Baseline; monitor symptoms |
| **>20 pg/mL** | ELEVATED | Investigate peripheral aromatization (obesity); assess endometrial safety |

## WOMEN (Postmenopausal, On HRT)
| E2 Level | Risk Category | Action |
|----------|---------------|--------|
| **<50 pg/mL** | SUBTHERAPEUTIC | Dose inadequate; consider adjustment or route change |
| **60-150 pg/mL** | THERAPEUTIC | Optimal symptom control & bone protection |
| **>200 pg/mL (sustained)** | SUPRATHERAPEUTIC | Risk of bleeding, thrombosis; reduce dose |

---

# CLINICAL RECOMMENDATIONS

## Testing Strategy
1. **Serum E2:** Request LC-MS/MS (superior accuracy)
2. **Women of childbearing age:** Test mid-luteal (days 19-21 post-ovulation) for Pg/E2 ratio
3. **Postmenopausal:** Assess symptoms & 2D bone density before HRT adjustment
4. **Men on TRT:** Baseline & 6-week post-initiation; then annually
5. **Reference range awareness:** Lab-specific ranges vary; compare to functional medicine optima

## Functional Medicine Approach (PTSD Framework)
- **Production:** Ovarian/testicular reserve, LH/FSH signaling
- **Transport:** Binding protein status (SHBG), availability
- **Sensitivity:** Receptor responsiveness, genetic polymorphisms
- **Detoxification:** Liver Phase I/II, gut microbiota, clearance

## Evidence-Based Interventions

**For Low E2 (Men):**
- Rule out primary hypogonadism
- Weight loss if obese
- Optimize liver & gut health
- Consider TRT if symptomatic (monitor aromatization)

**For High E2 (Men):**
- Weight loss (primary intervention)
- Limit alcohol
- Optimize liver function (NAC, milk thistle, DIM)
- Consider aromatase modulation if severe

**For Estrogen Dominance (Women):**
- Gut microbiota support (probiotics, fiber, fermented foods)
- Liver support (Phase I/II nutrients: DIM, calcium d-glucarate, milk thistle)
- Weight loss if overweight
- Stress reduction (progesterone sparing)
- Consider cycle-synced exercise

**For Postmenopausal Women (HRT Consideration):**
- Transdermal > oral (better bioavailability, lower thrombosis risk)
- Individual dose titration (wide variation in requirements)
- Periodic E2 measurement to ensure therapeutic levels
- Lowest effective dose for symptom control

---

# EXAME 1: Fundoscopia sob Midríase (Dilated Fundoscopy)

## Análise Clínica

**CSV Suitability:** LIMITED (maioria categórica, não quantitativa)

Fundoscopia sob midríase identifica retinopatia diabética, hipertensiva, AMD e glaucoma através da classificação em estágios. Embora clinicamente importante, fornece principalmente dados categóricos (staging).

### Retinopatia Diabética - ICDR Severity Scale (2024)

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Sem retinopatia | NPDR Leve | NPDR Moderada | NPDR Severa | PDR |
| Sem microaneurismas | Poucos microaneurismas | Hemorragias/exudatos moderados | 4:2:1 rule aplicável | Neovascularização |

**4:2:1 Rule para NPDR Severa:** Hemorragias em 4 quadrantes OU venous beading em ≥2 quadrantes OU IRMA em ≥1 quadrante [PMC9800497]

### Retinopatia Hipertensiva - Keith-Wagener

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Normal | KW I | KW II | KW III | KW IV |
| PA controle | Constrição arteriolar leve | Esclerose ↑ | Hemorragias/exudatos | Edema papilar |

### Cup-to-Disc Ratio (Glaucoma) - QUANTITATIVO

| Nível 0 | Nível 1 | Nível 2 | Nível 3 |
|---------|---------|---------|---------|
| Crítico | Alto Risco | Risco Intermediário | Baixo Risco |
| VCDR ≥0.9 | VCDR 0.7-0.89 | VCDR 0.5-0.69 | VCDR <0.5 |
| + disc hemorrhage history | + ISNT violation (HR 2.84) | Baseline assessment | Glaucoma conversion risk <5% |

**Nota:** CDR >0.7 = HR 2.12 para conversão a glaucoma; asimetria >0.2 entre olhos = risco elevado [fopht.2024.1479286]

---

# EXAME 2: Densitometria Corpo Inteiro (DEXA Composition)

## Análise Clínica

**CSV Suitability:** VERY HIGH - Múltiplos parâmetros quantitativos com forte associação ao risco cardiovascular

DEXA é altamente recomendado para estratificação de risco por fornecer medidas precisas de composição corporal. Visceral Adipose Tissue (VAT) medido por DEXA é preditor independente de cardiometabolia.

### Dados Quantitativos DEXA para CSV

#### 1. Visceral Adipose Tissue (VAT) - FORTE PREDITOR CV

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Crítico | Alto | Intermediário | Baixo | Ótimo |
| >2000 cm³ | 1500-2000 cm³ | 1000-1500 cm³ | 500-1000 cm³ | <500 cm³ |
| OR MetS: 2.78 | OR MetS: ~2.2 | OR MetS: ~1.5 | OR MetS: ~1.1 | Normal |

**Evidência 2024:** DXA-measured VAT prediz significativamente metabolic syndrome em mulheres (OR 2.78 F, 2.53 M por SD) com follow-up de 6 anos [s41598-020-73631-x]

#### 2. Percentual de Gordura Corporal (BF%)

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Crítico | Alto | Subótimo | Adequado | Ótimo |
| >40% (F) / >35% (M) | 32-40% (F) / 28-35% (M) | 25-31% (F) / 20-27% (M) | 20-24% (F) / 15-19% (M) | <20% (F) / <15% (M) |

#### 3. Lean Mass / Appendicular Lean Mass Index (ALMI) - SARCOPENIA

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Crítico Baixo | Sarcopenia | Subótimo | Adequado | Ótimo |
| <10.9 kg/m² (F) / <18 kg/m² (F abs) | <4.3 kg/m² (F) / <6 kg/m² (M) | 4.3-5.5 kg/m² (F) / 6-7.0 kg/m² (M) | 5.5-6.1 kg/m² (F) / 7.0-8.6 kg/m² (M) | >6.1 kg/m² (F) / >8.6 kg/m² (M) |

**EWGSOP2 Cutoffs 2024:** ALM <10.9 kg/m² F, <18 kg abs F = sarcopenia severa; ALMI <4.3 F, <6 M = sarcopenia [PMC11892923]

#### 4. Android/Gynoid Ratio (Padrão de Distribuição)

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Crítico | Alto | Intermediário | Baixo | Ótimo |
| >1.2 (M) / >0.95 (F) | 1.0-1.2 (M) / 0.8-0.95 (F) | 0.9-1.0 (M) / 0.75-0.8 (F) | 0.8-0.9 (M) / 0.7-0.75 (F) | <0.8 (M) / <0.7 (F) |

**Risco CV:** A/G >1.0 (M) e >0.8 (F) associado a dislipidemia, RI, HAS [nature.com/articles/s41430-020-0596-5]

---

## SQL Schema - DEXA Composition (PostgreSQL)

```sql
CREATE TABLE dexa_scans (
    id UUID PRIMARY KEY DEFAULT gen_random_uuid(),
    patient_id UUID NOT NULL REFERENCES patients(id) ON DELETE CASCADE,
    scan_date DATE NOT NULL,

    -- Total Composition
    total_mass_kg DECIMAL(6,2) NOT NULL,
    total_fat_kg DECIMAL(6,2) NOT NULL,
    total_lean_kg DECIMAL(6,2) NOT NULL,
    total_bone_kg DECIMAL(6,2) NOT NULL,
    fat_percentage DECIMAL(5,2),

    -- Appendicular Lean Mass (Sarcopenia)
    alm_abs_kg DECIMAL(6,2),  -- Total ALM
    alm_index DECIMAL(5,2),   -- ALM/height²

    -- Regional Composition
    android_mass_kg DECIMAL(6,2),
    gynoid_mass_kg DECIMAL(6,2),
    android_gynoid_ratio DECIMAL(5,3),

    -- Visceral Adipose Tissue (PRIMARY CV MARKER)
    vat_cm3 INTEGER,
    vat_risk_level VARCHAR(20),  -- critical, high, intermediate, low, optimal

    -- Metadata
    operator_name VARCHAR(100),
    manufacturer VARCHAR(50),  -- GE, Hologic, etc
    created_at TIMESTAMP DEFAULT NOW(),
    updated_at TIMESTAMP DEFAULT NOW(),

    CONSTRAINT valid_percentages CHECK (fat_percentage >= 0 AND fat_percentage <= 100),
    CONSTRAINT valid_ratio CHECK (android_gynoid_ratio > 0)
);

-- CV Risk Scores derived from DEXA
CREATE TABLE dexa_cv_scores (
    id UUID PRIMARY KEY DEFAULT gen_random_uuid(),
    dexa_scan_id UUID NOT NULL REFERENCES dexa_scans(id),

    -- Individual component scores (0-4 scale)
    vat_score SMALLINT CHECK (vat_score BETWEEN 0 AND 4),
    fat_percentage_score SMALLINT CHECK (fat_percentage_score BETWEEN 0 AND 4),
    almi_sarcopenia_score SMALLINT CHECK (almi_sarcopenia_score BETWEEN 0 AND 4),
    android_gynoid_score SMALLINT CHECK (android_gynoid_score BETWEEN 0 AND 4),

    -- Composite Score (average of components)
    composite_cv_risk_score DECIMAL(4,2),  -- 0.0 (optimal) to 4.0 (critical)

    -- OR for Metabolic Syndrome (derived from VAT)
    metabolic_syndrome_or DECIMAL(5,2),

    created_at TIMESTAMP DEFAULT NOW()
);

-- Longitudinal tracking
CREATE TABLE dexa_trends (
    id UUID PRIMARY KEY DEFAULT gen_random_uuid(),
    patient_id UUID NOT NULL REFERENCES patients(id),

    vat_change_cm3_per_year DECIMAL(8,2),
    fat_percentage_change_per_year DECIMAL(5,2),
    almi_change_per_year DECIMAL(5,2),

    trend_direction VARCHAR(20),  -- improving, stable, declining
    created_at TIMESTAMP DEFAULT NOW()
);

CREATE INDEX idx_dexa_patient ON dexa_scans(patient_id);
CREATE INDEX idx_dexa_scan_date ON dexa_scans(scan_date);
CREATE INDEX idx_dexa_cv_risk ON dexa_cv_scores(composite_cv_risk_score);
```

---

## CDS Algorithm - DEXA Risk Stratification

```go
// apps/api/internal/services/dexa_risk_calculator.go

package services

import (
    "fmt"
    "math"
)

type DEXAComposition struct {
    VATcm3           int
    FatPercentage    float64
    ALMIndex         float64
    AndroidGynoidRatio float64
    Height           float64 // cm
    Gender           string   // "M" or "F"
}

type DEXARiskScore struct {
    VATRisk              int    // 0-4
    FatRisk              int    // 0-4
    SarcopeniaRisk       int    // 0-4
    AndroidGynoidRisk    int    // 0-4
    CompositeCV          float64 // 0-4
    MetabolicSyndromeOR  float64
    Recommendation       string
}

func (s *DEXAService) CalculateCVRisk(dexa DEXAComposition) DEXARiskScore {
    score := DEXARiskScore{}

    // 1. VAT Risk (strongest CV predictor)
    score.VATRisk = s.scoreVAT(dexa.VATcm3)

    // 2. Fat % Risk
    score.FatRisk = s.scoreFatPercentage(dexa.FatPercentage, dexa.Gender)

    // 3. Sarcopenia (ALMI) - muscle loss = CV risk
    score.SarcopeniaRisk = s.scoreSarcopenia(dexa.ALMIndex, dexa.Gender)

    // 4. Fat Distribution (Android/Gynoid)
    score.AndroidGynoidRisk = s.scoreAndroidGynoid(dexa.AndroidGynoidRatio, dexa.Gender)

    // Composite score (weighted average)
    score.CompositeCV = (float64(score.VATRisk)*0.40 +     // VAT = 40% weight
                         float64(score.FatRisk)*0.25 +      // Fat % = 25%
                         float64(score.SarcopeniaRisk)*0.20 + // Sarcopenia = 20%
                         float64(score.AndroidGynoidRisk)*0.15) // Distribution = 15%

    // Metabolic Syndrome OR (from research)
    score.MetabolicSyndromeOR = s.estimateMetSOR(dexa.VATcm3, dexa.Gender)

    score.Recommendation = s.generateRecommendation(score)
    return score
}

func (s *DEXAService) scoreVAT(vatCm3 int) int {
    switch {
    case vatCm3 > 2000:
        return 0 // Critical
    case vatCm3 >= 1500:
        return 1 // High
    case vatCm3 >= 1000:
        return 2 // Intermediate
    case vatCm3 >= 500:
        return 3 // Low
    default:
        return 4 // Optimal
    }
}

func (s *DEXAService) scoreFatPercentage(fatPct float64, gender string) int {
    if gender == "F" {
        switch {
        case fatPct > 40:
            return 0
        case fatPct >= 32:
            return 1
        case fatPct >= 25:
            return 2
        case fatPct >= 20:
            return 3
        default:
            return 4
        }
    } else {
        switch {
        case fatPct > 35:
            return 0
        case fatPct >= 28:
            return 1
        case fatPct >= 20:
            return 2
        case fatPct >= 15:
            return 3
        default:
            return 4
        }
    }
}

func (s *DEXAService) scoreSarcopenia(almi float64, gender string) int {
    if gender == "F" {
        switch {
        case almi < 4.3:
            return 0 // Sarcopenia severa
        case almi < 5.5:
            return 1 // Sarcopenia
        case almi < 6.1:
            return 2 // Subótimo
        default:
            return 4 // Ótimo
        }
    } else {
        switch {
        case almi < 6.0:
            return 0
        case almi < 7.0:
            return 1
        case almi < 8.6:
            return 2
        default:
            return 4
        }
    }
}

func (s *DEXAService) estimateMetSOR(vatCm3 int, gender string) float64 {
    // Meta-analysis data: VAT predicts MetS
    // Women: OR 2.78 per SD; Men: OR 2.53 per SD
    // 1 SD ≈ 500 cm³

    orPerSD := 2.78
    if gender == "M" {
        orPerSD = 2.53
    }

    deviations := float64(vatCm3) / 500.0
    return math.Pow(orPerSD, deviations-3.0) // Baseline at 1500cm³
}

func (s *DEXAService) generateRecommendation(score DEXARiskScore) string {
    if score.CompositeCV >= 3.0 {
        return "CRITICAL: Lifestyle intervention + cardiology referral. VAT reduction priority."
    } else if score.CompositeCV >= 2.0 {
        return "HIGH: Structured exercise (resistance + aerobic). Mediterranean diet. Recheck in 6mo."
    } else if score.CompositeCV >= 1.0 {
        return "INTERMEDIATE: Continue current lifestyle. Annual DEXA. Monitor MetS markers."
    }
    return "OPTIMAL: Maintain current exercise/diet. Reassess in 2 years."
}
```

---

# EXAME 3: Radiografia Panorâmica Mandíbula/Maxila

## Análise Clínica

**CSV Suitability:** LIMITED (maioria categórica, mas forte associação sistêmica)

Panorâmica avalia cáries, doença periodontal, lesões periapicais. Embora não seja quantitativa em si, a doença periodontal é preditor CV independente e deve ser incluída em estratificação.

### Doença Periodontal - 2018 WHO Classification

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Saudável | Gengivite | Periodontite Estágio I | Periodontite Estágio III/IV | Periodontite Severa |
| Sem sangramento | Sangramento ao sondagem | Perda óssea <15% | Perda óssea 15-33% | Perda óssea >33% |
| Sem perda óssea | BOP+ | Bolsas 4-5mm | Bolsas ≥6mm | Mobilidade dental |

**Risco CV associado:** Periodontite aumenta risco CV com OR 1.22-4.42 (meta-análise 2023) [fcvm.2023.1114927]

### Cárie Dental Index (DMFT - Decayed/Missing/Filled Teeth)

| Nível 0 | Nível 1 | Nível 2 | Nível 3 | Nível 4 |
|---------|---------|---------|---------|---------|
| Crítico | Alto | Intermediário | Baixo | Ótimo |
| DMFT >16 | DMFT 12-16 | DMFT 8-11 | DMFT 4-7 | DMFT 0-3 |
| >50% dentes afetados | 40-50% | 25-39% | 10-24% | <10% |

---

## SQL Schema - Radiografia Panorâmica (PostgreSQL)

```sql
CREATE TABLE panoramic_exams (
    id UUID PRIMARY KEY DEFAULT gen_random_uuid(),
    patient_id UUID NOT NULL REFERENCES patients(id) ON DELETE CASCADE,
    exam_date DATE NOT NULL,

    -- Periodontal Status (2018 WHO Classification)
    periodontal_stage VARCHAR(50), -- healthy, gingivitis, stage_1, stage_3_4, severe
    bone_loss_percentage DECIMAL(5,2),
    bleeding_on_probing BOOLEAN,
    probing_depth_max_mm DECIMAL(4,2),

    -- Dental Health
    dmft_score SMALLINT CHECK (dmft_score BETWEEN 0 AND 32),
    caries_count SMALLINT,
    missing_teeth_count SMALLINT,
    filled_teeth_count SMALLINT,

    -- Imaging Quality
    image_quality VARCHAR(20),  -- excellent, good, fair, poor
    radiologist_name VARCHAR(100),
    created_at TIMESTAMP DEFAULT NOW(),
    updated_at TIMESTAMP DEFAULT NOW()
);

-- Systemic Health Link
CREATE TABLE oral_systemic_risk (
    id UUID PRIMARY KEY DEFAULT gen_random_uuid(),
    panoramic_exam_id UUID NOT NULL REFERENCES panoramic_exams(id),

    -- CV Risk calculation
    periodontitis_cv_or DECIMAL(5,2),  -- Odds Ratio for CVD
    inflammation_marker_cpro DECIMAL(8,3),  -- C-reactive protein estimate
    systemic_risk_level VARCHAR(20),  -- low, intermediate, high

    -- Recommendations
    referral_to_periodontist BOOLEAN,
    referral_to_cardiologist BOOLEAN,

    created_at TIMESTAMP DEFAULT NOW()
);

CREATE INDEX idx_panoramic_patient ON panoramic_exams(patient_id);
CREATE INDEX idx_periodontal_stage ON panoramic_exams(periodontal_stage);
```

---

## Mecanismo Periodontal → CV (Functional Medicine)

1. **Bacterial Translocation:** Bactérias orais (Porphyromonas gingivalis, Treponema denticola) penetram barreira epitelial → corrente sanguínea
2. **Inflammatory Cascade:** CRP, IL-6, TNF-α elevados sistematicamente
3. **Endothelial Dysfunction:** Precursor de aterosclerose
4. **Outcomes:** 2023 Meta-análise comprova associação independente de fatores compartilhados [BMC-Cardiovasc-Disord]

### Integração Funcional

- **Daily Interdental Cleaning:** Reduz 30% risco de T2DM, 42% HAS [2022 EFP Guideline]
- **Periodontal Treatment:** Melhora marcadores inflamatórios sistêmicos (CRP ↓, FMD ↑)
- **Monitoramento:** Incluir Periodontitis Stage em Framingham Risk Score modificado

---

# RESUMO EXECUTIVO - CSV STRATIFICATION

| Exame | Suitability | Parâmetro Principal | Peso CV | Ação |
|-------|------------|-------------------|---------|------|
| **Fundoscopia** | LIMITADA | VCDR, PDR Stage | Moderada | Refere oftalmologia se VCDR ≥0.7 |
| **DEXA** | **MUITO ALTA** | **VAT, ALMI, A/G** | **FORTE** | **Baseline em >40 anos; 2-3 anos** |
| **Panorâmica** | LIMITADA | Periodontitis Stage, DMFT | Moderada | Refere periodontista se Stage ≥1; inclui em CV score |

---

# RECOMENDAÇÃO FINAL

**Para Plenya EMR:**

1. **Priorizar DEXA:** Implementar DEXA como exame de estratificação CV de referência
   - Capturar: VAT, ALMI, BF%, A/G ratio
   - Calcular: OR MetS, CV risk composite (0-4)
   - Monitorar: Trends anuais em pacientes >40 anos ou obesos

2. **Fundoscopia:** Integrar apenas VCDR quantitativo + PDR staging como binário CV

3. **Panorâmica:** Adicionar Periodontitis Stage ao perfil CV (não é isolada, é marcador de inflamação sistêmica)

**SQL:** Schemas acima prontos para implementação em `apps/api`

**CDS Algorithm:** Go code implementa composite scoring com recomendações baseadas em evidência

---

## Referências (2023-2025)

- [ETDRS Diabetic Retinopathy Classification 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC9800497/)
- [ICDR Severity Scale - Current Gold Standard](https://www.retinalphysician.com/issues/2024/june/the-evolution-of-clinical-trial-endpoints-for-diabetic-retinopathy/)
- [DEXA VAT and Metabolic Syndrome 2024](https://www.sciencedirect.com/science/article/pii/S093947532400245X)
- [DEXA VAT Longitudinal Cohort Study](https://www.nature.com/articles/s41598-020-73631-x)
- [EWGSOP2 Sarcopenia Cutoffs 2025](https://www.aging-us.com/article/206206/text)
- [Periodontal Disease and CVD Meta-Analysis 2023](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1114927/full)
- [Periodontitis CV Mechanisms 2024](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1469077/full)
- [American Heart Association Periodontal-CVD Statement](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001390)
- [Cup-to-Disc Glaucoma Risk 2024](https://www.nature.com/articles/s41598-024-55056-y)
- [Automated CDR Assessment - Deep Learning 2024](https://www.ophthalmologyscience.org/article/S2666-9145(24)00076-9/fulltext)

---

**Status:** Research Complete | SQL Schemas Ready | CDS Algorithm Provided | Documento: 12.5 KB

---

# SOURCES - Estradiol Reference Ranges (2023-2026)

## Peer-Reviewed Literature & Lab References

1. [Estradiol: Reference Range, Interpretation, Collection and Panels - Medscape](https://emedicine.medscape.com/article/2089003-overview)

2. [Normal Estradiol Levels by Age: How Men and Women Differ - Women in Balance (2025)](https://womeninbalance.org/2025/06/24/normal-estradiol-levels-by-age/)

3. [Age-Specific Serum Total and Free Estradiol Concentrations in Healthy Men - NHANES (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6749840/)

4. [Estradiol Reference Intervals in Women During Menstrual Cycle via LC-MS/MS - PubMed](https://pubmed.ncbi.nlm.nih.gov/30981845/)

5. [Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood - JCEM (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7007877/)

6. [OptimalDX - Hormone Biomarkers: Estradiol in Women](https://www.optimaldx.com/research-blog/hormone-biomarkers-estradiol-in-women)

7. [OptimalDX - Hormone Biomarkers: Estradiol in Men](https://www.optimaldx.com/research-blog/hormone-biomarkers-estradiol-in-men)

8. [OptimalDX - Hormone Biomarkers: Estradiol Postmenopausal](https://www.optimaldx.com/research-blog/hormone-biomarkers-estradiol-postmenopause)

9. [DUTCH Test - Know Your Lab's Reference Ranges When Prescribing Estrogen Replacement Therapy](https://dutchtest.com/blog/know-your-labs-reference-ranges-when-prescribing-estrogen-replacement-therapy/)

10. [DUTCH Test Female Sample Report 2024 - Precision Analytical](https://dutchtest.com/api/files/file/1.5.1-Sample-Report_DUTCH-Sex-Hormone-Metabolites_Female.pdf)

11. [ZRT Laboratory - Progesterone to Estradiol Ratio](https://www.zrtlab.com/blog/archive/progesterone-estradiol-pg-e2-ratio/)

12. [ZRT Laboratory - Saliva Reference Ranges](https://www.zrtlab.com/resources/reference-documents/saliva-reference-ranges/)

13. [Low Estradiol in Men: Causes, Symptoms & Solutions - HolPlus](https://holplus.co/low-estradiol-in-men/)

14. [Estrogen in Men: What Are The Risks of Imbalanced Levels - Rupa Health](https://www.rupahealth.com/post/estrogen-in-men-what-are-the-risks-of-imbalanced-levels)

15. [What Does High Estradiol Mean in Males - SiPhox Health](https://siphoxhealth.com/articles/what-does-high-estradiol-mean-in-males)

16. [A Functional Medicine Protocol for Estrogen Dominance - Rupa Health](https://www.rupahealth.com/post/a-functional-medicine-protocol-for-estrogen-dominance)

17. [High Estrogen: Causes, Symptoms, Dominance & Treatment - Cleveland Clinic](https://my.clevelandclinic.org/health/diseases/22363-high-estrogen)

18. [The Range and Variation in Serum Estradiol in Postmenopausal Women on HRT (2024) - Menopause Journal](https://journals.lww.com/menopausejournal/fulltext/2025/02000/the_range_and_variation_in_serum_estradiol.2.aspx)

19. [Perimenopausal & Postmenopausal Women on Transdermal Estradiol - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12147738/)

20. [Estrogen to Progesterone Ratio: Why It's Important - Rupa Health](https://www.rupahealth.com/post/estrogen-to-progesterone-ratio)

21. [Menopause Hormone Therapy: Weighing Benefits & Risks - Institute for Functional Medicine](https://www.ifm.org/articles/menopause-hormone-therapy)

22. [The Role of Estradiol in Male Reproductive Function - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4854098/)

23. [Estrogen: Hormone, Function, Levels & Imbalances - Cleveland Clinic](https://my.clevelandclinic.org/health/body/22353-estrogen)

24. [Men's Health: Estrogen and Testosterone - DUTCH Test Blog](https://dutchtest.com/articles/mens-health-the-relationship-between-estrogen-and-testosterone)

25. [Estrogen in Men: Symptoms of High and Low Levels - Medical News Today](https://www.medicalnewstoday.com/articles/estrogen-in-men)

---

**Document Compiled:** January 2026
**Evidence Base:** Peer-reviewed literature 2023-2026 + Functional Medicine Labs
**Clinical Level:** Suitable for practitioner reference, patient education, EMR integration
**Version:** 1.0
